133 related articles for article (PubMed ID: 9402864)
1. The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases.
Furst DE
Br J Rheumatol; 1997 Nov; 36(11):1196-204. PubMed ID: 9402864
[TBL] [Abstract][Full Text] [Related]
2. Effect of methotrexate use on the development of type 2 diabetes in rheumatoid arthritis patients: A systematic review and meta-analysis.
Baghdadi LR
PLoS One; 2020; 15(7):e0235637. PubMed ID: 32628710
[TBL] [Abstract][Full Text] [Related]
3. Combining ts- and a bDMARD in refractory rheumatoid arthritis: an unusual adverse event.
Sztejkowski C; Sibilia J; Danion F; Mertz P; Elodie F; Kassegne L; Boyer P; Puéchal X; Gottenberg JE; Scherlinger M
Rheumatology (Oxford); 2024 May; 63(6):e185-e187. PubMed ID: 38070160
[No Abstract] [Full Text] [Related]
4. Severe bone marrow suppression due to methotrexate toxicity following aceclofenac-induced acute kidney injury.
Manappallil RG; Prasan D; Peringat J; Biju IK
BMJ Case Rep; 2018 Jun; 2018():. PubMed ID: 29871962
[TBL] [Abstract][Full Text] [Related]
5. Comparison of subcutaneous and oral methotrexate initiation in rheumatoid arthritis in current practice.
Vidal-Montal P; Thomas M; Combier A; Steelandt A; Miceli-Richard C; Molto A; Narváez J; Nolla JM; Allanore Y; Avouac J
Joint Bone Spine; 2023 Dec; 90(6):105620. PubMed ID: 37482177
[No Abstract] [Full Text] [Related]
6. Predicting treatment response to methotrexate: are we closer to solving the enigma?
Myasoedova E
Rheumatology (Oxford); 2024 May; 63(6):1479-1480. PubMed ID: 38019954
[No Abstract] [Full Text] [Related]
7. Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response.
Scher JU; Nayak RR; Ubeda C; Turnbaugh PJ; Abramson SB
Nat Rev Rheumatol; 2020 May; 16(5):282-292. PubMed ID: 32157196
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate in rheumatoid arthritis-another brick in the wall.
Rubbert-Roth A
Lancet Rheumatol; 2023 Apr; 5(4):e173-e175. PubMed ID: 38251514
[No Abstract] [Full Text] [Related]
9. Methotrexate for Prevention of Cardiovascular Events.
Huang Y; Chan AW; Shear NH
N Engl J Med; 2019 Jun; 380(23):2277. PubMed ID: 31167067
[No Abstract] [Full Text] [Related]
10. A Case of Severe Organ Dysfunction and Skin Lesions Due to Methotrexate Toxicity.
C Barros TR; Ribeiro YP; Oliveira VC; A Lopes M
Cureus; 2024 May; 16(5):e60008. PubMed ID: 38854245
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate induced lung injury in a patient with primary CNS lymphoma: a case report.
Chhabra P; Law AD; Suri V; Malhotra P; Varma S
Mediterr J Hematol Infect Dis; 2012; 4(1):e2012020. PubMed ID: 22550565
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate for the neurologist.
Jesuthasan A; Baheerathan A; Auger S; Dorsey R; Coker R; Selvapatt N; Viegas S
Pract Neurol; 2024 May; ():. PubMed ID: 38821881
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous manifestations of systemic methotrexate toxicity.
Jain S; Pyle HJ; Evans JC; Gao W; Mauskar MM
JAAD Int; 2024 Jun; 15():179-181. PubMed ID: 38651037
[No Abstract] [Full Text] [Related]
14. An ulcerating skin tumour in a patient with rheumatoid arthritis.
Schenning LCM; Ottevanger R; Quint KD; Tas SW
Ann Rheum Dis; 2024 Feb; ():. PubMed ID: 38316532
[No Abstract] [Full Text] [Related]
15. Cardiac health in rheumatoid arthritis: a Doppler perspective on steroids and methotrexate.
Bourg C; Serrano E; Donal E
Acta Cardiol; 2023 Nov; ():1-3. PubMed ID: 37961892
[No Abstract] [Full Text] [Related]
16. Malic Acid for the Treatment of Rheumatic Diseases.
de Carvalho JF; Lerner A
Mediterr J Rheumatol; 2023 Dec; 34(4):592-593. PubMed ID: 38282938
[No Abstract] [Full Text] [Related]
17. Methotrexate and penicillin interaction.
Dawson JK; Abernethy VE; Lynch MP
Br J Rheumatol; 1998 Jul; 37(7):807. PubMed ID: 9714372
[No Abstract] [Full Text] [Related]
18. Methotrexate recognition by the human reduced folate carrier SLC19A1.
Wright NJ; Fedor JG; Zhang H; Jeong P; Suo Y; Yoo J; Hong J; Im W; Lee SY
Nature; 2022 Sep; 609(7929):1056-1062. PubMed ID: 36071163
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of antifolate recognition and transport by PCFT.
Parker JL; Deme JC; Kuteyi G; Wu Z; Huo J; Goldman ID; Owens RJ; Biggin PC; Lea SM; Newstead S
Nature; 2021 Jul; 595(7865):130-134. PubMed ID: 34040256
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and predictors of adverse events with methotrexate mono- and combination-therapy for rheumatoid arthritis: a systematic review.
Sherbini AA; Sharma SD; Gwinnutt JM; Hyrich KL; Verstappen SMM
Rheumatology (Oxford); 2021 Sep; 60(9):4001-4017. PubMed ID: 33909898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
